Handbook of Clinical medicine

transmission. Diagnosis: Clinical. Microscopy of tissue samples (skin, bone marrow) for parasite. Antibody detection in VL (indirect fl uores- cence, ELISA, western blot, direct agglutination test, or immuno- chromatographic test) is limited due to: 1 Ab levels detectable for years after cure, cannot distinguish VL relapse/active infec- tion. 2 Tests are +ve in many with no history of VL. 3 Serology may be Ωve if HIV +ve. Treatment: Liposomal amphoterin (single Fig 9.33 Visceral leishmaniasis. dose), oral miltefosine, pentavalent antimonials (resistance in India). The WHO Kala-azar Elimination Programme (including Reproduced with permis- sion from World Health donated liposomal amphotericin) has achieved a 75% reduction Organization. © World in new cases of VL. Health Organization. http:// Human African trypanosomiasis (HAT, sleeping sickness) www.who.int/leishmaniasis/ Infection with Trypanosoma protozoan parasites16, trans- visceral_leishmaniasis/en/ mitted by the tsetse fl y in sub-Saharan Africa. Divided into: • Rhodesiense HAT, incubation <21d, high fever, GI disturbance, lymphadenopathy, headache. Chancre at bite site in ~84%, maculopapular rash. Progresses to myo- pericarditis, arrhythmias, and neurological symptoms. • Gambiense HAT, chronic disease in African population, presents years after infec- tion (can present with acute febrile illness in travellers). Low-grade fever. Sleep disorder: reversal of sleep–wake cycle, uncontrollable sleep episodes. Weakness,
